title: Sugammadex approved to reverse NMBA effects.
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Thompson
mesh_terms: D000732:Androstanols / Q000009:adverse effects; D018849:Controlled Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D007275:Injections, Intravenous; D009466:Neuromuscular Blocking Agents / Q000037:antagonists & inhibitors*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects; D000077123:Rocuronium; D000077122:Sugammadex; D014481:United States; D014486:United States Food and Drug Administration; D014673:Vecuronium Bromide / Q000009:adverse effects; D047408:gamma-Cyclodextrins / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000732:Androstanols; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D014673:Vecuronium Bromide; D000077123:Rocuronium